Needham analyst Serge Belanger maintained a Buy rating on KalVista Pharmaceuticals (KALV) today and set a price target of $28.00. The company’s shares closed last Wednesday at $9.98.
According to TipRanks.com, Belanger is a 2-star analyst with an average return of -0.8% and a 36.5% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Collegium Pharmaceutical, and Zynerba Pharmaceuticals.
KalVista Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $28.00.
See today’s analyst top recommended stocks >>
The company has a one-year high of $27.25 and a one-year low of $5.61. Currently, KalVista Pharmaceuticals has an average volume of 142.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.
